Nearly a minute of cheers, whistles, and applause filled the main auditorium at the American Society of Clinical Oncology's 2026 Annual Meeting in Chicago on May 31 when Dr. Brian M. Wolpin, director of the Hale Family Center for Pancreatic Cancer Research at Dana-Farber Cancer Institute, revealed that a new pill had cut the risk of death by 60 percent in metastatic pancreatic cancer. The drug, daraxonrasib, represents something oncologists have chased for decades: a way to finally tackle the mutated KRAS protein that fuels tumor growth in more than 90 percent of pancreatic cancer cases.
The standing ovation—so unexpected it wasn't even scheduled into Wolpin's talk—signals a turning point in one of medicine's cruelest battles. Pancreatic cancer kills roughly 50,000 Americans every year, and patients with metastatic disease face a five-year survival rate of just 3 percent. The disease has long resisted treatment because the KRAS protein, as one trial investigator colorfully described it, is "like a shiny ball—you can't stick anything to it. It just kind of slides off." For decades, this molecular slipperiness made KRAS untouchable.
Daraxonrasib changes that equation. It's the first in a new class of "RAS(ON) multi-selective inhibitors"—drugs that switch off the active form of KRAS across multiple variants, and even in tumors with no detectable RAS mutation. This breadth matters enormously: it means the drug could benefit virtually every pancreatic cancer patient, regardless of their tumor's genetic makeup.
The Phase 3 RASolute 302 trial, conducted by California-based Revolution Medicines and published simultaneously in The New England Journal of Medicine, tested the drug against standard chemotherapy in 500 patients whose cancer had progressed despite prior treatment. The numbers were striking. In patients with RAS G12 mutations, median overall survival stretched to 13.2 months on daraxonrasib compared to just 6.6 months on chemotherapy. Progression-free survival was 7.3 months versus 3.5 months. Perhaps most tellingly, only 1.2 percent of patients discontinued daraxonrasib due to side effects, compared to 11.2 percent who stopped chemotherapy because they couldn't tolerate it.
The response from the oncology community has been electric. ASCO's chief medical officer Julie R. Gralow told reporters the data was not merely "a home run" but "a grand slam." Dr. Rachna Shroff, chief of hematology/oncology at the University of Arizona Cancer Center and ASCO's designated commentator, called it "a game changer in pancreatic cancer." Social media clips of the ovation drew millions of views, with prominent physicians describing the moment as witnessing a historic shift in cancer care.
The drug's profile extends beyond the conference. Former U.S. Republican Senator Ben Sasse of Nebraska spoke publicly on 60 Minutes about experiencing less pain while taking daraxonrasib, bringing the clinical triumph into public conversation. As Revolution Medicines launches a special access program, oncologists are already fielding a flood of requests from patients and colleagues seeking the pill before broader approval.
For a disease that has long seemed immovable, daraxonrasib represents something rare in cancer medicine: not incremental progress, but a fundamental unlocking of a target that had resisted decades of effort. The standing ovation was not routine applause. It was recognition that the landscape has shifted.